SMAD4 and cancer: Nevertheless, Smad4 immunostain was markedly (1.4-fold and 1.9-fold, respectively) weaker in the tumorous tissues from early and advanced cancer stages compared with their corresponding normal specimens (Figure 1; p < 0.001).